Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
Caroline Ogilvie Michie
No relevant relationships to disclose
Shahneen Kaur Sandhu
No relevant relationships to disclose
William R. Schelman
No relevant relationships to disclose
L Rhoda Molife
No relevant relationships to disclose
George Wilding
Research Funding - Merck
Aurelius Gabriel Omlin
No relevant relationships to disclose
Vikram Kansra
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
David G. Brooks
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Stanley B. Kaye
No relevant relationships to disclose
Johann Sebastian De Bono
No relevant relationships to disclose
Robert Michael Wenham
Honoraria - Merck